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ABSTRACT
Purpose For passive dry powder inhalers (DPIs) entrainment
and emission of the aerosolized drug dose depends strongly on
device geometry and the patient’s inhalation manoeuvre. We
propose a computational method for optimizing the entrain-
ment part of a DPI. The approach assumes that the pulmo-
nary delivery location of aerosol can be determined by the
timing of dose emission into the tidal airstream.
Methods An optimization algorithm was used to iteratively
perform computational fluid dynamic (CFD) simulations of
the drug emission of a DPI. The algorithm seeks to improve
performance by changing the device geometry. Objectives
were to achieve drug emission that was: A) independent of
inhalation manoeuvre; B) similar to a target profile. The sim-
ulations used complete inhalation flow-rate profiles generated
dependent on the device resistance. The CFD solver was
OpenFOAM with drug/air flow simulated by the Eulerian-
Eulerian method.
Results To demonstrate the method, a 2D geometry was op-
timized for inhalation independence (comparing two breath
profiles) and an early-bolus delivery. Entrainment was both
shear-driven and gas-assisted. Optimization for a delay in the
bolus delivery was not possible with the chosen geometry.
Conclusions Computational optimization of a DPI geometry
for most similar drug delivery has been accomplished for an
example entrainment geometry.
KEY WORDS boundary-condition . cost-function . DPI .
entrainment . optimization
ABBREVIATIONS
BC Boundary Condition
CFD Computational Fluid Dynamics
COPD Chronic Obstructive Pulmonary Disease
DPI Dry Powder Inhaler
EE Eulerian-Eulerian
EL Eulerian–Lagrangian
KTGF Kinetic Theory for Granular Flow
PIF Peak Inhalation Flow
INTRODUCTION
Establishment of Design Objectives for Inhaled Drug
Delivery
Dry powder inhaler (DPI) therapy has increased in impor-
tance as a therapeutic modality for both pulmonary diseases
such as asthma, and systemic diseases such as diabetes. In
particular, the adoption of the Montreal Protocol banning
the use of chlorofluorocarbon propellants accelerated devel-
opment of DPIs as an alternative to the difficult reformulation
of pressurized metered dose inhalers (1,2). In recent years, the
suitability of DPIs for aerosolization and delivery of high drug
payloads has been exploited, including the introduction of
inhaled insulin and antibiotic products (3,4). There has also
been an interest in developing bioequivalent (generic) DPI
products as more established products reach the end of patent
exclusivity. There is therefore a need to design and optimize
DPI devices to achieve a variety of therapeutic outcomes in a
diverse patient population ranging from those with healthy
respiratory function to those with compromised respiratory
function.
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When designing a DPI, it is important to understand how
particular design elements influence the release (emission) of
aerosolized drug and consequently the device performance. It
is therefore necessary to predict drug release profiles for par-
ticular entrainment geometries and to relate these profiles to
the pharmaceutical objectives of drug delivery (two examples
include: achieving bioequivalence, or maximizing peripheral
airway deposition for systemic drug delivery). When
predicting drug release profiles the entrainment mechanisms
must be understood. In general, authors distinguish between
gas-assisted, shear-force driven, capillary and mechanical flu-
idization (5). The fluidization mechanisms for different devices
may be found in literature (e.g. (6,7)).
When designing an inhaler, several objectives have to be
considered: First, drug should deposit in similar pulmonary
airways, independent of the patient’s pulmonary function
and ability to use the device (objective A). For example, van
den Berge (8) stresses the importance of targeting the small
airways for effective treatment of asthma and chronic obstruc-
tive pulmonary disease (COPD). Second, the drug release
profile should be similar to a (pre-defined) desired released
profile, for example an early-bolus release (objective B) (9).
Additional objectives are to achieve de-agglomeration of drug
powder (10,11) and low-manufacturing costs but these are
beyond the scope of this paper.
It is accepted that the particle size distribution of the emit-
ted aerosol is a significant factor in determining the site of
deposition in the pulmonary airways (12), and the degree of
de-agglomeration during device actuation is crucial in deter-
mining the particle size. However, the emission-time profile of
that aerosol (even one with a size distribution suitable for
targeting delivery to specific airways) is an area of DPI and
inhaler design that remains under-explored. With the
Adaptive Aerosol Delivery System (13), peripheral airway de-
position of aerosol produced using a vibrating mesh nebulizer
can be enhanced by limiting emission and inhalation of aero-
sol to 50 – 80% of the inspiratory cycle. A number of authors
argue that delivering drug to a particular location of the lung
correlates well to the pharmacokinetic profile (14). It has been
shown that the timing of release correlates with the deposition
location for nebulizers. Scheuch et al. (15) found that the site of
drug deposition may be influenced by the timing of the bolus
delivery. Heyder et al. (16) investigated in which ‘volumetric
lung depth’ a bolus of drug deposits. Drug was introduced into
the inhaled airflow after a particular fraction of the total vol-
ume was inhaled. Heyder et al. (16) showed experimentally
that particle deposition was higher when the aerosol bolus
penetrated deep into the lung. Similarly, Brand et al. (12) de-
termined in which ‘lung volume element’ drug is likely to
deposit by determining the probability of a particle depositing
in the lung as a function of volumetric lung depth for an
aerosol with a constant drug concentration. In the case of a
bolus delivery the instant at which the drug was introduced
into the airstream correlated (16) with the region to which
drug was deposited.
Consequently, in this study it is assumed that the lung
location to which drug will be delivered correlates well
with the point in the inhaled tidal volume into which drug
i s in t roduced dur ing inha la t ion . Al though not
disregarding the importance of the de-agglomeration pro-
cesses, the argument is valid in cases where the DPI de-
signer cannot easily influence the size of drug particles, if
we assume a powder that has been optimized for its ease
of dispersion (17,18). Following this argument, it is impor-
tant to optimize DPIs to release drug at the correct instant
with respect to the fraction of inhaled volume (x) rather
than with respect to the inhalation time (t).
Computational Fluid Dynamics for DPI Design
Computational fluid dynamic (CFD) analysis refers to the use
of computational techniques to solve fluid flow problems. The
application of CFD techniques in inhaled drug delivery has
increased in recent years for prediction of pulmonary aerosol
deposition, but also to improve understanding of aerosoliza-
tion processes, e.g. to predict the performance of DPIs (19).
CFD has also been used to assess device resistance (20,21),
track the path of individual particles (21) and to investigate
particle de-agglomeration in DPIs (10,22,23).
In CFD analysis for DPIs the particulate (drug) phase can
either be ignored (a single phase approach considering air flow
only) or modelled using a multiphase approach. The majority
of reported studies using multiphase approaches for simula-
tion of DPIs have used Eulerian–Lagrangian (EL, particle-
tracking) approaches (24). EL approaches make it difficult to
study the fluidization process of a powder bed due to the large
number of particle-particle interactions. It is for this reason
that we have recently introduced Eulerian-Eulerian (EE) ap-
proaches (9,25) for investigation of DPIs.
In the EE approach, the drug particles are modelled as a
second continuous phase and the interaction between the gas
and the granular phase is modelled. A new variable, the vol-
ume fraction (α) is introduced to keep track of the local frac-
tion of drug phase. EE approaches are often used in the study
of other fluidization processes (26,27). As in other CFD ap-
proaches the domain of interest is split into a large number of
cells. For each cell the Eulerian-Eulerian solver solves for a
number of variables including α, the average velocity of drug
particles vdrug and the average velocity of the gaseous phase
vair . As shown in Fig. 1 the value of α indicates the number
of particles in that cell. In the EE approach, all phases, includ-
ing the particulate phases, are modelled as continuous fluids
and consequently mass, momentum and energy conservation
laws are applied to all phases. In many cases, these equations
look similar to the standard Navier–Stokes equations. The
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kinetic theory for granular flow (KTGF) (28) is one method to
model the constitutive behaviour of a granular phase in the
EE approach. KTGF makes predictions about stresses and
phase interaction terms in the governing equations of the
fluid.
For modelling purposes, the applied boundary condi-
tion at the outlet of the inhaler is usually a constant flow
rate or a transient pressure boundary condition (25). A
constant flow rate boundary condition is prescribed in
regulatory inhaler testing (29,30). However, physiological-
ly relevant inhalation flow-rate profiles are more complex.
As shown by de Koning et al. (31,32) the peak inhalation
flow (PIF), total inhalation time and other inhalation pro-
file variables depend on the device resistance and the type
of disease. It is of interest to develop a DPI modelling
approach that can incorporate the complexity of inter-
individual variability in inhalation performance and
flow-rate profiles. For this reason the experimental data
from de Koning et al. (31) was employed to model
resistance-dependent inhalation profiles and to establish
the outlet boundary conditions for a CFD simulation. In
particular it is of interest to simulate the drug release
profiles during the simulated inhalations in order to guide
the design and optimization of different DPI geometries.
There has been relatively little prior work on the use of
computational optimization methods for the design of DPIs.
The aim of this study was to address the knowledge gap in the
application of computational fluid dynamics (CFD) in the nu-
merical optimization of DPIs. In order to achieve the aim,
optimization cost functions have been developed for the quan-
titative assessment of the performance of device entrainment
geometries for a range of simulated inhalation profiles. As an
example of the methodology, these cost functions have been
applied in an optimization framework in order to improve the
drug emission performance of a simple entrainment
geometry.
METHODS
Cost Function Development
The goal of numerical optimization is to find an argument x
that minimizes a cost function C(x), where x consists of a
number of design variables. In engineering applications the
cost C measures some quality of a design. For example, C
could measure the manufacturing cost or energy consump-
tion. In this study we only consider drug delivery performance
of a DPI device. We propose two cost functions that measure
entrainment and emission performance. The optimization
goal is to minimize these functions. Cost function A prefers
devices that can emit drug to similar pulmonary airways (12)
(i.e. volumetric lung depth), independent of the patient’s respi-
ratory function. Cost function B prefers devices that achieve a
desired drug release profile (e.g. early bolus). The cost func-
tions are developments of earlier concepts presented by the
authors of this study (9,25).
For the first design objective, the goal is to achieve the ‘most
similar drug delivery’, i.e. the drug should penetrate to the
same pulmonary region for different patients. To test this ob-
jective a large number of patients with different inhalation
manoeuvres could be considered. However, to illustrate the
approach only two inhalation profiles, 1 and 2, are considered
in this study.
In general, patients have different inhalation profiles; i.e.
when they inhale through the device, they produce different
volumetric flow rates Q1 (t) and Q2 (t) (see example profiles in
Fig. 2a) leading to different drug emission rates (dM/dt)
Fig. 1 Idealized representation of
the EE approach. The volume
fraction α indicates the density of
particles.
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(Fig. 2a). The integral (Eq. 1) gives the inhaled volume as a
function of time, t:
V i tð Þ ¼
Z t
0
Q i t
0
 
dt0 ð1Þ
where i= patient 1 or 2. The total inhaled volume (see Fig. 2b)
is given by Eq. 2:
V i; Tot ¼
Z ∞
0
Q i t
0
 
dt0 ð2Þ
After carrying out a CFD simulation of entrainment, the
emitted dose profile Mi can be calculated. Mi is the mass of
drug that has left the device at one point and can be expressed
as either a function of timeMi (t) or inhaled volumeMi (V) (see
Fig. 2c). MTot is the total drug amount in the primed dosing
unit (i.e. capsule, blister, metering cup). Mi (V) may be scaled
along the V-axis by defining the scaled volume (Eq. 3):
x ¼ V i
V i;Tot
where 0≤x≤1 ð3Þ
This gives Mi(V) = Mi(x Vi,Tot), (see Fig. 2d).
The device will ideally have released the same amount of
drug for patients 1 and 2 when the same fraction x of the total
inhaled air Vi,Tot has been inhaled. It follows that identical dose
emission would be represented by Eq. 4, for all x.
M1 x V 1;Tot
  ¼ M2 x V 2;Tot  ð4Þ
Since it is impossible to achieve Eq. 4 exactly, the design
objective is, therefore, to minimize the difference between the
drug release profiles (Eq. 5) for all x:
c xð Þ ¼ M1 x V 1;Tot
 
−M2 x V 2;Tot
   ð5Þ
Figure 2d shows the same release profiles as in Fig. 2c, but
as a function of scaled volume x. It is hoped to minimize
c(x) = 0 for all x. A possible cost-function to achieve this is
therefore Eq. 6:
CA ¼
Z 1
0
c xð Þdx ¼
Z 1
0
M1 xV 1;Tot
 
−M2 xV 2;Tot
  dx ð6Þ
Minimizing CA will ensure ‘most similar drug delivery’ for
different patients. Note that since CFD solves discretized
Fig. 2 Idealized representations of inhalation flow rate (Q), inhaled volume (V tð Þ ), released drug (M) and scaled volume (x) as functions of time or each other.
Sample data for clarification purposes only. This Fig. is similar to Fig. 1 in (1). (a) Flow rate and release rate vs. time. (b) Volume of inhalation vs. time. (c)
Released drug vs. volume. (d) Released drug vs. scaled volume.
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versions of the governing equations in practice the integral
(Eq. 6) has to be approximated as a summation.
Minimizing the cost function CA guarantees a device air-
flow geometry that can achieve the highest similarity of the
emission-volume profile. However, it cannot be guaranteed
that this emission profile is also a desired one. It depends on
the desired therapeutic application whether, for example, ei-
ther an early bolus delivery (to reach peripheral airways) or
continuous emission (to achieve deposition throughout all air-
ways) is required.We should, therefore, also consider compar-
ing the release profile with a desired, idealized release profile.
As an illustration, if for a particular medical application an
early bolus delivery of drug is desired, an idealised early bolus
profile (see Fig. 2d) can be defined using Eq. 7:
M3 xð Þ ¼ Mtot
x
x0
if x < x0
Mtot if x≥x0
( )
ð7Þ
This is a ‘ramp’ function, i.e. M3 (x) represents an early-
bolus profile, which increases linearly from 0 to x0 and is
constant from x0 to 1. This is more realistic compared to (9),
where an ideal step function was used. To evaluate how close-
ly the emitted dose profile from our device matches the
idealised profile the cost function given by Eq. 8 has been
used:
CB ¼
Z 1
0
c xð Þdx ¼
Z 1
0
M1 xV 1;Tot
 
−M3 xð Þ
 dx ð8Þ
Minimizing cost function CB gives a geometry with the
desired release behaviour. To also achieve ‘most similar drug
delivery’ between different patients requires simultaneous
minimization of cost function CA.
Boundary Conditions
When conducting a CFD analysis, boundary conditions (BCs)
have to be specified. At the inlet a (constant) atmospheric
pressure is usually specified. The applied boundary condition
at the outlet should resemble the flow-field generated by a real
patient inhaling through the device.
In many experimental and computational studies a con-
stant flow rate Q or a constant pressure drop Δp is applied
(10,21,33). A constant flow rate boundary condition simplifies
experimental studies and regulatory testing (29,30). However,
if much of the drug entrainment occurs before the PIF is
reached, or if the PIF is not sustained for very long, then using
a constant flow rate BC may not model the real entrainment
behaviour accurately. Zimarev et al. (25) went some way to
addressing this issue by applying a pressure ramp BC of con-
stant dpdt for a fixed simulation time to represent the start of an
inhalation. This is a good improvement if entrainment occurs
early in the inhalation manoeuvre. However, some devices
have not released all the drug dose before PIF is reached
(34). A fixed simulation time is therefore only acceptable if
most of the drug leaves the device within the simulated time.
A possible solution to these problems is to specify the flow rate
Q (t) as a function of time at the outlet and model a whole
inhalation profile (or at least the first part of the profile until
drug emission is complete).
The applied Q (t) BC should be as realistic as possible. In
practice measured flow rate profiles vary significantly as a
function of device resistanceR, i.e. a lower flow rate is expected
to be produced by any given patient for high resistance devices
and vice versa. For example, de Koning et al. (31,32) plotted the
flow rate as a function of time for two different device resis-
tances and health of patient. Several important (averaged)
parameters of the inhalation profile were reported, such as
PIF, the time when the PIF occurs tPIF, and total time of
inhalation ttot as a function of resistance and patient health.
Thus, it is possible to fit a polynomial to these points. The
following procedure was applied (see Fig. 3a):
1. Determine the resistance R in Q R ¼ ﬃﬃﬃﬃﬃΔpp by running a
steady-state CFD simulation (using simpleFOAM from
OpenFOAM (35)) where a constant pressure difference
Δp is applied. Q is found from the simulation. Hence, R
¼ ﬃﬃﬃﬃﬃΔpp =Q is calculated.
2. Interpolate the data from de Koning et al. (31,32) to find
relevant flow field parameters (PIF, tPIF, ttot) for the partic-
ular value of R and patients’ disease state.
3. Model a flow rate function Q (t) from these parameters.
4. Account for a fraction of bypassing air: Many DPI devices
allow the majority of inhaled air flow to bypass the drug
entrainment geometry, e.g. (21).
In principle, a wide range of functions could be fitted to the
parameters in step 3 to model a flow rate function Q (t). In this
case, however, Q (t) was modelled using two piecewise-defined
3rd order polynomials f (t) and g (t):
Q tð Þ ¼
f tð Þ if t < tPI F
g tð Þ if t≥ tPI F
0 if t≥ ttot
8<
:
9=
; ð9Þ
The first polynomial, f (t), links the onset of the inhalation
with the PIF. The second polynomial connects the PIF with
the end of the inhalation. The coefficients of the polynomials f
(t) and g (t) can be determined numerically by imposing a
number of conditions at the start and end of the inhalation:
1. At t = 0: Q(0) = f(0) =0
2. At t = ttot: i.e. Q (ttot) = g (ttot) =0
3. Q (t) drops slowly towards the end of the inhalation, i.e.
Q ′ (ttot) = 0.
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At the transition of the two polynomials, i.e. at point
(tPIF, PIF), it is required that
4. Q (t) is continuous, i.e. f (tPIF) = g (tPIF) = PIF
5. Q (tPIF) is a maximum, i.e. f′ (tPIF) = g′ (tPIF) = 0.
6. It was also assumed that the second derivative is continu-
ous, i.e. f″ (tPIF) =g″ (tPIF).
Using these conditions, the coefficients of the polynomials
were determined. Fig. 3b shows example fits to data from de
Koning et al. (31,32) for different device resistances.
In this study the method described above, using de
Koning’s data (31,32), was used to generate the idealized in-
halation profile Q1 (t) for an average patient for each device
geometry considered. The second inhalation profile Q2 (t) was
generated in a similar way, but with a lower PIF. The PIF of
Q 2 tð Þ was chosen to be one standard deviation below that of
Q1 (t). The time to PIF tPI F and the duration ttot were the same
for both Q 1 tð Þ and Q 2 tð Þ (in contrast to the example profiles
shown in Fig. 2).
CFD and Optimization
CFD Methodology
As an example implementation, the cost functions (section 2.1)
and the dynamically generated boundary conditions (section
2.2) were applied in a CFD optimization routine. First, a sim-
ple 2D geometry was parametrized in terms of five design
variables: a; b; c; d; e. Using a Python-script (36) the geometry
was generated depending on these design parameters.
BlockMesh (OpenFOAM (35)) was used to mesh the geome-
try. The Eulerian-Eulerian solver twoPhaseEulerFoam
(OpenFOAM) was used to simulate the drug release through
the device for high and low flow-rate boundary conditions.
Transient boundary conditions were applied using the
OpenFOAM library swak4Foam (37). A Python-script (36)
determined the drug-release profiles as a function of the scaled
inhaled volume x for each boundary condition and then cal-
culated the cost functions CA and CB .
A total cost function Ctot= wACA+ wBCB was calculated
(where wA and wB are weightings). The cost function Ctot
was minimized by systematically changing the geometry using
a steepest gradient-descent method, see e.g. (38).
Definition of Design Space for Optimization and CFD Studies
A simple DPI device was considered in this study (Fig. 4). The
geometry was chosen so that it could represent a range of types
of design of existing DPI. The device consists of an inlet, an
entrainment area and an outlet. A fixed volume of drug of
3 mm2 was initially placed into the entrainment area (note
that in 2D simulations, a volume may be represented by an
area A). The size of the outlet is a, the height of the capsule/
blister and the inlet is h. The capsule/blister may or may not
be filled with drug completely. The separation between the
drug surface and the upper boundary of the capsule is c. d is
the angle between the inlet tube and the capsule. The amount
of drug A filled into the device was constant. The height, h, of
t h e c a p s u l e w a s t h e r e f o r e c a l c u l a t e d f r om
h ¼ c þ A= e þ aþ bð Þ.
Fig. 3 Determining the boundary condition and examples of release profiles for different resistance R. (a) Determine transient boundary conditions. (b)
Modelled Q (t) function for different resistances R3 - R8. Piecewise defined polynomials were fitted to data from de Koning et al. (31,32).
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Table I shows the lower and upper boundaries of the
design variables. The values of these boundaries were
chosen to give geometries of realistic sizes. Daniher and Zhu
(5) identified different types of drug entrainment in DPIs, i.e.
shear-driven and gas-assisted entrainment. This parameter-
ized device is designed to allow different entrainment behav-
iour for different values of the design variables. For example, a
gas-assisted entrainment may be expected when e and c are
small and d is close to 9
Å
0. Such a geometry approximates the
bathtub shaped blister found in some DPIs where the foil lid is
pierced to from an inlet and outlet (39). On the other hand,
shear-driven entrainment, e.g. (40), may be expected when e
and c are large. In addition, the resistance may be influenced
by varying any of the parameters, since the latter change the
airflow paths within the entrainment region of the DPI device.
Eulerian-Eulerian Modelling
When the volume fraction of the drug phase is high, the drug
may significantly influence the flow field. For this reason an
Eulerian-Eulerian (EE) approach was used in this study to
simulate drug release profiles. When the volume fraction of
drug is very high, the EE approach is more computationally
efficient than an Eulerian–Lagrangian (EL) particle tracking
approach. The models and parameters used in this study are
given in Table II. Lactose powder was simulated in this study
in order to compare the computational results with
experimental results from (41) for validation purposes. While
the real lactose powder comprises of particles with a distribu-
tion of particle sizes, in this study a mono-dispersed powder
was simulated. Lactose particles are usually used as diluent,
also known as carrier particles (42,43) and have high average
diameter compared to the drug, excluding the fines. In this
study de-agglomeration was not simulated. Although a simpli-
fication for the purposes of the current study, it was assumed
that the drug particles would de-agglomerate from their lac-
tose carrier during or after entrainment. Delivery of active
drug is therefore assumed to be proportional to the amount
of entrained lactose powder.
Optimization Algorithm
In this study a steepest gradient descent optimization algo-
rithm was used to minimize the total cost function Ctot.
Successful implementation of gradient descent relies on deter-
mining the search direction p which is the direction of steepest
descent p=−∇Ctot and on deciding a suitable step length α
(38). To enhance the performance of the optimization algo-
rithm, all five design variables were scaled to confine values
between 0 and 1. For example, a*, the scaled version of design
variable a, was calculated using Eq. 10.
a* ¼ a−alow
ahigh−alow
ð10Þ
alow and ahigh are the lower and upper boundary of a, respec-
tively. Similarly, all other design variables were scaled. This
gives a vector of scaled design variables:
x ¼ a* ; b* ; c* ; d* ; e*  ð11Þ
If, at step k of an optimization process, the current set of
design variables is xk = (a*, b*, c*, d*, e*), a new choice of
design variables, for the next step (k +1), may then be evalu-
ated as follows (38):
xkþ1 ¼ xk þ α p ð12Þ
In this study, the search direction p was determined by
approximating − ∇Ctot using a finite difference method.
Using a backtracking line search a suitable step length α was
determined (38). Since this is a constrained optimization prob-
lem a penalty term was applied if the constraints were
exceeded. In order to avoid convergence to a local minimum,
the same optimization algorithm was repeated for different
(random) initial values of the design variables.
RESULTS & DISCUSSION
Experimental Validation of the CFD Approach
The CFD method developed and reported in this study has
been validated by comparison with entrainment experiments
performed by Tuley et al. (41). In Tuley’s study, a constant
pressure gradient dpdt was applied at the outlet of three different
entrainment geometries. Each geometry permitted entrain-
ment by a different combination of shear and gas assisted
mechanisms. The entrainment geometries were transparent
and a video camera was used to record the entrainment of
particles. In order to validate the CFD approach chosen in this
study, one of these entrainment geometries was modelled
using the CFD approach described in Sections 2.3.1 – 2.3.3.
For the geometry selected (see Fig. 5) the initial entrainment
Fig. 4 Parameterized entrainment geometry.
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mechanism is gas-assisted, but it transitions to shear driven as
evacuation progresses.
Figure 5 shows images of an entrainment device for different
times as lactose powder (16% fines) was entrained when a pres-
sure gradient of dpdt =−30 kPa s
−1 was applied at the outlet of the
device (41). For comparison, the numerical results (EE CFD)
are shown next to the experimental results. Tuley et al. (41)
recorded the first frame at t ¼ 0:033s, and therefore all CFD
modelling timepoints are given relative to this time. The plots of
streamlines shown in Fig. 5 have been compiled from the air
velocity solution (EE CFD). The streamlines are curves that are
tangent to the velocity vector of the air at any given time.
Typically, streamlines converge when the speed of the fluid
increases. Therefore, plots of streamlines may be used to ana-
lyse how the flow is affected by the presence of the drug powder:
Initially, the volume fraction of drug α is 0.49, see Table II.
Once drug is moved away from the powder bed surface, a thin
channel of air is shaped. The streamlines converge towards
each other in this channel. Thus, air flows preferably through
this channel. The results from the simulation appear to be
similar to the experimental results with the formulated powder
being released over similar timescales and in a similar process in
the model as in the experimental observations.
mesh Independence Study
The accuracy and the computational costs of CFD simulations
are influenced by the type of chosen mesh (44) . In general, a
high mesh density results in more detailed and accurate re-
sults, but also higher computation time. It is important to
verify that the numerical results are independent of mesh res-
olution. Small changes in the mesh should not result in large
changes in the results. A mesh-independence study may be
conducted by plotting one variable for different meshes.
Fig. 6 shows the result of a mesh-independence study: For a
p a r t i c u l a r g e om e t r y a* ; b* ; c* ; d* ; e*
  ¼ 0:5; 0:5;ð
0:5; 0:5; 0:5Þ, the number of cells used to mesh the geometry
was varied. It appears that meshes with more than 3750 cells
are sufficient to achieve mesh independence.
Exploration of Design Space for DPI Optimization
Before the design space could be explored two parameters
had to be set. First, the relative weightings wA and wB of
the cost functions CA and CB had to be set. Second, the
value of x0 in the ideal drug release profile M3 (x) had to
be set (see Eq. 7). Initially, the weightings were set to
w = (wA, wB) = (1, 1), i.e. both cost functions were weighted
equally. However, CA tended to be (much) smaller than
CB. This implies that for the modelled (pierced blister)
geometry, objective A (similar drug release for different
patients) is comparatively easier to achieve than objective
B (s imilari ty to a desired drug release prof i le ) .
Consequently, the weighting was changed to w = (40, 1)
in a second optimization process. These weighting values
imply that most emphasis is put on achieving objective A.
In this case objective B is (almost) ignored.
In addition, two different values for x0, the duration of
drug release in the ideal release function M3 (x), were ex-
amined (see Eq. 7). A value of x0 = 0.2 gives an ideal early
bolus drug release, while a higher value of x0 = 0.5 gives a
more continuous release profile. As an example, the results
Fig. 5 Comparison of experimental data (Tuley et al. (41), Fig. 6) with nu-
merical simulation. The inlet is the right leg, the outlet is the left leg. Tuley et al.
(41) filled lactose powder (16% fines) into the entrainment device.
Fig. 6 Mesh independence study.
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for the scaled release profile and the corresponding cost
functions are presented in Fig. 7 when just a single param-
eter, the length of the compartment end e∗, was varied,
while all other parameters were kept constant. Fig. 7a
shows that early delivery of drug is achieved for small
values of e∗, while a more continuous delivery is achieved
for larger values of e∗. Fig. 7b indicates a trade-off between
costs CA and CB: A high value of e
∗ results in a continuous
drug delivery and hence a small value of CB (for x0 = 0.5).
However in this regime, of longer duration delivery, differ-
ences between the emission profiles for patients 1 and 2
become more significant and so CA increases.
The results show that powder entrainment can be influ-
enced by changing design parameters. In particular, a better
early bolus delivery may be achieved. This phenomenon is
consistent with experimental findings. For example, Tuley et al.
(41) compared different entrainment devices and found that
both the fluidization process and the timescale of fluidization
is influenced by the choice of geometry.
Optimization Results
Optimization of the entrainment geometry of a DPI was
attempted to achieve two objectives. One objective was to
deliver drug to similar parts of the airways for different pa-
tients (objective A). The second objective was to deliver drug
to a specific location in the airways (objective B). Optimization
was conducted for four different combinations of the
weightings w= (wA, wB), of the cost functions (CA and CB),
and the delivery duration, x0 (see Figs. 8, 9 and 10). In general,
the optimized geometry depends on the weightings of the cost
function w and the duration x0. Figs. 8, 9 and 10 show opti-
mization results for different values of w and x0.
Figure 8 shows the optimized geometry (a) and the corre-
sponding scaled drug release profiles (b) when the cost func-
tions were equally weighted w= (1, 1), i.e. Ctot= CA+ CB, and
an early bolus delivery (x0 = 0.2) was assumed. The ‘high flow
rate’ profile corresponds to the drug release profile for patient
1 with average inhalation flow, Q1 (t). The ‘low flow rate’
Fig. 7 Release profile and costs for different values of the length of the compartment end e*. All other parameters were kept constant:
(a*, b*, c*, d*) = (0.76, 0.26, 0.20, 0.38). (a) Example release profiles for four different values of e*. The inhalation profiles applied were those of a weaker
patient (Q2(t)). (b) Value of the cost functions CA and CB as e* is varied.
Fig. 8 C= CA+ CB, x0 = 0.2, the
optimal set of design variables is
x= (0.68, 0.10, 0.64, 0.47, 0.08).
(a) The optimal geometry and the
volume fraction α at time t = 0.2s.
(b) Scaled drug release profile for
high and low flow rate.
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profile corresponds to the drug release profile for patient 2,
with lower inhalation flow Q 2 tð Þ. Similarly, Fig. 9 shows the
optimized geometry (a) and the corresponding scaled drug
release profiles (b) for the same weighting, but a more contin-
uous drug delivery (x0 ¼ 0:5 ). Comparing the optimized ge-
ometries for these two cases suggests that a continuous drug
delivery is achieved by increasing the length of the compart-
ment end e. Drug that is placed within the compartment end
is slowly entrained by a shearing action during inhalation.
When the CA and CB weightings of w = (40,1) were chosen
(i.e. emphasis was put on objective A to achieve maximum
similarity of drug release in the same inhaled volume elements
for patients with different inhalation manoeuvres), approxi-
mately the same optimized geometry was discovered, inde-
pendent of the timing value x0 that was chosen. Figure 10
shows the optimized geometry and the corresponding scaled
drug release profiles when weightings of w = (40,1) and a
timing value of x0 = 0.2 was chosen. However, it was found
that very similar results were discovered for a timing value of
x0 = 0.5 and thus only one figure of this type is shown. The
scaled drug release profiles indicate that good agreement of
release profiles of different patients was achievable, but opti-
mization objective B, i.e. achieving a target release profile, was
effectively ignored due to the low relative weighting. In order
to achieve more continuous drug delivery higher variations in
the delivery for different patients have to be accepted for this
type of geometry (as shown in Fig. 9b).
For the example geometry chosen in this study, no device
was found that effectively delayed the drug delivery in the
scaled representation. Therefore, only a bolus-delivery at the
beginning of the inhalation cycle or a continuous delivery
from the beginning of the inhalation cycle are possible.
Developing a passive DPI geometry that allows a delay in
timing of the drug delivery will be the subject of future
research.
CONCLUSIONS
In this work, a computational method has been developed and
applied for in silico optimization of a simple DPI geometry.
Particularly, two cost functions that quantify performance of
DPIs and a dynamic CFD boundary condition were devel-
oped. We have shown that CFD design optimization can be
applied to DPI design. Validation is an important issue when
considering numerical simulations. Due to the lack of experi-
mental results, validation was only possible to a limited extent
in this study. Nevertheless, the computational approach
Fig. 9 C= CA+ CB, x0 = 0.5, the
optimal set of design variables is
x= (0.55, 0.0, 0.79, 0.34, 0.93).
(a)The optimal geometry and the
volume fraction α at time t = 0.2s.
(b) Scaled drug release profile for
high and low flow rate.
Fig. 10 C = 40 CA+
CB x0 = 0.2 and x0 = 0.5, the
optimal set of design variables is
x= (0.76, 0.29, 0.21, 0.38, 0.0).
(a) The optimal geometry and the
volume fraction α at time t = 0.2s.
(b) Scaled drug release profile for
high and low flow rates.
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reported was shown to predict the drug entrainment behav-
iour; mechanistically, qualitatively, and with respect to the
time-profile from the limited set of reported experimental ob-
servations. Multiphase CFD modelling is a challenging prob-
lem and the accuracy of predictions is limited by the quality of
the model and the computational power available. The limi-
tations of the current EE approach were that cohesive inter-
actions and de-agglomeration of particles were ignored. In
addition, only a mono-dispersed drug powder was considered
in this study. However, the computational efficiency of the EE
approach reported in this study shows excellent promise for
modelling entrainment compared to previously reported EL
approaches.
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